Cirius Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2015-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://ciriustx.com
A Study of MSDC-0602K to Assess Glycemic Control and Cardiovascular Outcomes in Patients With Pre-T2D or T2D and NAFLD/NASH
Phase 3
Not yet recruiting
- Conditions
- Type2 DiabetesNASH - Nonalcoholic SteatohepatitisNonalcoholic SteatohepatitisNon-Alcoholic Fatty Liver Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2019-05-31
- Last Posted Date
- 2021-07-12
- Lead Sponsor
- Cirius Therapeutics, Inc.
- Target Recruit Count
- 1800
- Registration Number
- NCT03970031
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC-0602K in Patients With NASH
Phase 2
Completed
- Conditions
- Non-alcoholic Fatty Liver DiseaseNon-alcoholic SteatohepatitisNASH - Nonalcoholic Steatohepatitis
- Interventions
- Drug: Placebo
- First Posted Date
- 2016-05-27
- Last Posted Date
- 2020-09-16
- Lead Sponsor
- Cirius Therapeutics, Inc.
- Target Recruit Count
- 392
- Registration Number
- NCT02784444